News Releases

These are news releases that are related to our company, pipeline and investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Sep 27, 2018

Summary Toggle aTyr Pharma Announces Pulmonary Sarcoidosis as Disease Indication for Phase 1b/2a Clinical Study and Educational Webinar

Conference Call and Webcast Featuring Leading Sarcoidosis Expert Dr. Daniel Culver on October 8, 2018 at 8:00 am ET SAN DIEGO , Sept. 27, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on
Sep 20, 2018

Summary Toggle aTyr Pharma to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

SAN DIEGO , Sept. 20, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay Shukla , M.D., M.S., president and chief executive officer,
Aug 30, 2018

Summary Toggle aTyr Pharma to Present at the Baird 2018 Global Healthcare Conference

SAN DIEGO , Aug. 30, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay Shukla , M.D., M.S., president and chief executive officer,
Aug 14, 2018

Summary Toggle aTyr Pharma Announces Second Quarter 2018 Operating Results and Provides Corporate Update

Conference Call Today at 5:00 p.m. ET / 2:00 p.m. PT SAN DIEGO , Aug. 14, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced operating results
Aug 8, 2018

Summary Toggle aTyr Pharma to Host Conference Call and Webcast of Second Quarter 2018 Financial Results on August 14, 2018

SAN DIEGO , Aug. 08, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report its second quarter financial results on Tuesday,
Jul 31, 2018

Summary Toggle aTyr Pharma Appoints Jill Broadfoot as Chief Financial Officer

SAN DIEGO , July 31, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Jill Broadfoot has joined aTyr as Chief Financial Officer.
Jul 26, 2018

Summary Toggle aTyr Pharma Presents Positive Lung and Skin Findings with ATYR1923 in a Translational Animal Model at the Scleroderma Foundation National Patient Education Conference

SAN DIEGO , July 26, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a poster presentation at the Scleroderma Foundation National Patient
Jun 26, 2018

Summary Toggle aTyr Pharma Announces Positive Phase 1 Data for ATYR1923 Therapeutic Candidate

ATYR1923 Well-Tolerated at all Doses Tested, with No Significant Adverse Events Pharmacokinetic Profile Supports Potential Once-Monthly Dosing SAN DIEGO , June 26, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of
May 31, 2018

Summary Toggle aTyr Pharma to Present at Jefferies 2018 Global Healthcare Conference

SAN DIEGO , May 31, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay Shukla , M.D., M.S., President and Chief Executive Officer,
May 17, 2018

Summary Toggle aTyr Pharma Presents Poster on Preclinical Data from ATYR1923 Program at American Thoracic Society 2018 International Conference

ATYR1923, an Immuno-Modulatory Therapeutic Candidate with Potential in Interstitial Lung Diseases SAN DIEGO , May 17, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological